Compare Abeona Therapeutics Inc (ABEO) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bitdeer Technologies Group — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Bitdeer Technologies Group trades at $12.16 (market cap $3.13B). The key difference: Bitdeer Technologies Group is far larger — about 8.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ABEO | BTDR | |
|---|---|---|
Market Cap | $373.32M | $3.13B |
Sector | Health | Technology |
52-Week High | $7.23 | $25.90 |
52-Week Low | $4.17 | $7.28 |
Enterprise Value | $228.22M | $4.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BTDR trades at $14.25, up 2.89% today, with a bullish technical signal despite recent earnings misses. The company reported Q1 2026 revenue growth of 170% year-over-year to $188.9 million but posted a net loss. Analyst consensus is strongly bullish with an 81.82% buy rating and a $23.40 price target, suggesting significant upside. Recent developments include expansion into AI cloud infrastructure and new data center agreements in Norway and Canada.
The outlook for BTDR is mixed, with strong revenue growth and strategic AI expansion offset by persistent net losses and negative profit margins. Key risks include execution challenges in new ventures and sensitivity to Bitcoin market volatility. The stock presents a high-risk, high-reward opportunity, supported by Wall Street optimism but requiring careful monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
